Molecular predictors of long-term survival in glioblastoma multiforme patients

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Lu, Jie ^a   Cowperthwaite, Matthew C ^a,b   Burnett, Mark G ^a   Shpak, Max ^a,b,c  

^a NeuroTexas Institute   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Fresh Pond Research Institute Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ALGORITHM; BRAIN TUMOR; CHILD; CLUSTER ANALYSIS; COHORT ANALYSIS; DNA METHYLATION; FACTUAL DATABASE; FEMALE; GENE DOSAGE; GENOTYPE; GLIOBLASTOMA; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PHENOTYPE; POINT MUTATION; PRINCIPAL COMPONENT ANALYSIS; REGRESSION ANALYSIS; REPRODUCIBILITY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHILD; CLUSTER ANALYSIS; COHORT STUDIES; DATABASES, FACTUAL; DNA METHYLATION; FEMALE; GENE DOSAGE; GENOTYPE; GLIOBLASTOMA; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; POINT MUTATION; PRINCIPAL COMPONENT ANALYSIS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85016129383     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154313     Document Type: Article

References (51)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109:93–108. PMID: 15685439
2. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002; 62:6205–10. PMID: 12414648
3. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002; 8:180–7. PMID: 11801556
4. Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci 2011; 18:66–70. doi: 10.1016/j.jocn. 2010.04.050 PMID: 20888234
5. Adeberg S, Bostel T, König L, Welzel T, Debus J, Combs SE. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? Radiat Oncol 2014; 9:95. doi: 10.1186/1748-717X-9-95 PMID: 24758192
6. Babu R, Sharma R, Karikari IO, Owens TR, Friedman AH, Adamson C. Outcome and prognostic factors in adult cerebellar glioblastoma. J Clin Neurosci 2013; 20:1117–21. doi: 10.1016/j.jocn.2012.12. 006 PMID: 23706183
7. Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) 2009; 151:1349–58.
8. Ullén H, Mattsson B, Collins VP: Long-term survival after malignant glioma. A clinical and histopathological study on the accuracy of the diagnosis in a population-based cancer register. Acta Oncol 1990; 29:875–8. PMID: 2261201
9. Kraus JA, Wenghoefer M, Schmidt MC, von Deimling A, Berweiler U, Roggendorf W, et al. Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J Neurol 2000; 247:455–60. PMID: 10929275
10. Senger D, Cairncross JG, Forsyth PJ: Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype? Cancer J 2003; 9:214–221. PMID: 12952306
11. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The Somatic Genomic Landscape of Glioblastoma. Cell 2013; 155:462–477. doi: 10.1016/j.cell.2013.09.034 PMID: 24120142
12. Amelot A, De Cremoux P, Quillien V, Polivka M, Adle-Biassette H, Lehmann-Che J, et al. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. PLoS One 2015; 10:e0130596. doi: 10.1371/journal.pone.0130596 PMID: 26158269
13. Erson-Omay EZ, Ca layan O, Schultz N, Weinhold N, Omay SB, Özduman K, et al. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro Oncol 2015; 17:1356–1364. doi: 10.1093/neuonc/nov027 PMID: 25740784
14. Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, et al. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol 2000; 48:89–94. PMID: 11083071
15. Lai RK, Chen Y, Guan X, Nousome D, Sharma C, Canoll P, et al. Genome-wide methylation analyses in glioblastoma multiforme. PLoS One 2014; 9.
16. Niyazi M, Zehentmayr F, Niemöller OM, Eigenbrod S, Kretzschmar H, Schulze-Osthoff K, et al. MiRNA expression patterns predict survival in glioblastoma. Radiat Oncol 2011; 6:153. doi: 10.1186/1748-717X-6-153 PMID: 22074483
17. Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR. Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications. Front Oncol 2015; 5-:1–9.
18. Patel VN, Gokulrangan G, Chowdhury SA, Chen Y, Sloan AE, Koyutürk M, et al. Network signatures of survival in glioblastoma multiforme. PLoS Comput Biol 2013; 9:e1003237. doi: 10.1371/journal.pcbi. 1003237 PMID: 24068912
19. Smith AA, Huang Y-T, Eliot M, Houseman EA, Marsit CJ, Wiencke JK, et al. A novel approach to the discovery of survival biomarkers in glioblastoma using a joint analysis of DNA methylation and gene expression. Epigenetics 2014; 9:37–41.
20. Verhaak RGW, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17:98–110. doi: 10.1016/j.ccr.2009.12.020 PMID: 20129251
21. Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, et al. Transcriptional diversity of long-term glioblastoma survivors. Neuro Oncol 2014; 16:1186–95. doi: 10.1093/neuonc/nou043 PMID: 24662514
22. Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol 2013; 15:469–79. doi: 10.1093/neuonc/nos317 PMID: 23408861
23. Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, et al. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer 2014; 135:1822–31. doi: 10.1002/ijc.28836 PMID: 24615357
24. Zhao Q, Shi X, Xie Y, Huang J, Shia B, Ma S. Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA. Brief Bioinform 2015; 16:291–303. doi: 10. 1093/bib/bbu003 PMID: 24632304
25. Kleihues P, Burger PC, Plate KH, Ohgaki H, Cavenee WK. Pathology and Genetics of Tumours of the Nervous System. Lyon: International Agency for Research on Cancer;1997.
26. The Cancer Genome Atlas: http://cancergenome.nih.gov/
27. Shpak M, Goldberg MM, Cowperthwaite MC: Rapid and convergent evolution in the Glioblastoma multiforme genome. Genomics 2015; 105:159–167. doi: 10.1016/j.ygeno.2014.12.010 PMID: 25576655
28. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 2012; 28:311–7. doi: 10. 1093/bioinformatics/btr665 PMID: 22155872
29. Cingolani P, Platts A, Coon M, Nguyen T, Wang L, Land SJ, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 2012; 6:80–92. doi: 10.4161/fly.19695 PMID: 22728672
30. Shpak M, Hall AW, Goldberg MM, Derryberry DZ, Ni Y, Iyer VR, et al. An eQTL analysis of the human glioblastoma multiforme genome. Genomics 2014; 103:252–263. doi: 10.1016/j.ygeno.2014.02.005 PMID: 24607568
31. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4:249–64. PMID: 12925520
32. Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. Ann Stat 2015; 32:407–499.
33. Chawla N: Data Mining for Imbalanced Datasets: An Overview. In Data Mining and Knowledge Discovery Handbook SE—40. Edited by Maimon O, Rokach L. Springer US;2005:875–886.
34. Getis A, Ord JK: The Analysis of Spatial Association by Use of Distance Statistics. Geogr Anal 2010; 24:189–206.
35. Hartigan JA, Hartigan PM: The Dip test of unimodality. Ann Stat 1985; 13:70–84.
36. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain 2007; 130:2596–606. PMID: 17785346
37. Chambless LB, Kistka HM, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC. The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. J Neuro Oncol 2015; 121:359–364.
38. Stuehr DJ: Mammalian nitric oxide synthases. Biochim Biophys Acta 1999; 1411:217–30. PMID: 10320659
39. Dixit R, Wilkinson G, Cancino GI, Shaker T, Adnani L, Li S, et al. Neurog1 and Neurog2 control two waves of neuronal differentiation in the piriform cortex. J Neurosci 2014, 34:539–53. doi: 10.1523/ JNEUROSCI.0614-13.2014 PMID: 24403153
40. Wang D, Han S, Peng R, Jiao C, Wang X, Han Z, et al. DUSP28 contributes to human hepatocellular carcinoma via regulation of the p38 MAPK signaling. Int J Oncol 2014; 45:2596–604. doi: 10.3892/ijo. 2014.2653 PMID: 25230705
41. Kuhajda FP, Piantadosi S, Pasternack GR: Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 1989; 321:636–41. PMID: 2475778
42. Martin S, Cosset EC, Terrand J, Maglott A, Takeda K, Dontenwill M. Caveolin-1 regulates glioblastoma aggressiveness through the control of alpha(5)beta(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an alpha(5)beta(1) integrin antagonist. Biochim Biophys Acta 2009; 1793:354–67. doi: 10.1016/j.bbamcr.2008.09.019 PMID: 18992284
43. Huse JT, Phillips HS, Brennan CW: Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011; 59:1190–9. doi: 10.1002/glia.21165 PMID: 21446051
44. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9:157–73. PMID: 16530701
45. Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999; 1:44–51. PMID: 11550301
46. Zhang C, Zhang J, Hao, Shi Z, Wang Y, Han L, et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med 2012; 10:119. doi: 10.1186/1479-5876-10-119 PMID: 22681957
47. Zhang C, Zhang J, Zhang A, Shi ZD, Han L, Jia ZF, et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Caner 2010; 9:229.
48. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009; 41:899–904. doi: 10.1038/ng.407 PMID: 19578367
49. Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 2009; 41:905–8. doi: 10.1038/ng.408 PMID: 19578366
50. Lin Q, Wagner W: Epigenetic Aging Signatures Are Coherently Modified in Cancer. PLoS Genet 2015; 11:e1005334. doi: 10.1371/journal.pgen.1005334 PMID: 26110659
51. Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol 2014; 32:644–652. doi: 10.1038/nbt.2940 PMID: 24952901